Prof. Dr. Martin Schulz, FFIP, FESCP
Curriculum Vitae
April 2021
PERSONAL INFORMATION
Home
Address
Fraunhoferstr. 1 F
14612
Falkensee
Germany
EDUCATION AND TRAINING
Institution |
Dates
of |
Major Field of Study |
Degree |
Date |
University of Hamburg |
1978 – 1982 |
Study of Pharmacy |
BS in Pharmacy |
April 1982 |
University of Hamburg |
1984 – 1986 |
Study of Medicine |
|
|
DOCTORAL DISSERTATION
Dr. rer. nat. (PhD) in Pharmacology, University of Hamburg, August 1988, titled
"Interactions of selected histamine H2-receptor antagonists with the cytochrome P-450 system and potential effects on
the
pharmacokinetics of non-steroidal anti-inflammatory drugs."
PROFESSIONAL EXPERIENCE
Name and Location of Institution |
Rank or Position |
Dates of Service |
Community Pharmacy (Apotheke am Muemmelmannsberg), Hamburg |
Pharmacy Intern |
May – October 1982 |
University of Hamburg, University Medical Center Eppendorf, Institute of Pharmacology, Hamburg |
Pharmacy Intern/ Graduate Student |
November 1982 – April 1983 |
Hospital St. Adolf-Stift, Department of Pharmacy, Reinbek |
Clinical Pharmacist |
June 1983 – September 1984 |
University of Hamburg, University Medical Center, Institute of Pharmacology and Institute of Legal Medicine, Hamburg |
PhD-student |
October 1984 – |
ABDA – Federal Union of German Associations of Pharmacists, Berlin |
Head, Center for Drug Information and Pharmacy Practice (ZAPP) |
October 1988 – 2008 |
German Institute for Drug Use Evaluation (DAPI), Berlin |
Director Pharmacy |
2002 – present |
Goethe-University Frankfurt, Department of Pharmacology |
Adjunct Professor |
2005 – present |
ABDA – Federal Union of German Associations of Pharmacists, Berlin |
Department of Medicine, |
2008 – present |
Drug Commission of German Pharmacists (AMK), Berlin |
Chairman |
2009 – present |
Freie Universität Berlin, |
Adjunct / Honorary Professor |
2019 – present |
LICENCES
German "Approbation"
May 1983
Licence as pharmacist (RPh), State of Hamburg
Expert/Board Certified in Pharmacology
July 1989
German Society for Experimental and Clinical Pharmacology and Toxicology
Drug Information Pharmacist/Specialist
July 1993
Chamber of Pharmacists Hesse, Frankfurt at Main, Germany
AWARDS AND HONORS
André
Bédat Award
2020
FIP’s
highest pharmaceutical practice award, awarded every two years
[Dtsch. Ärztebl. 2020; 117
(47): A 2303 / B 1943.]
Adjunct Fellow (Honorary) University of Technology Sydney (UTS)
2020
Graduate School of
Health
Best Publication Prize (1st prize)
2020
Chronic Heart Failure Working Group, German Cardiac Society (DGK)
[Pharm. Ztg. 2020; 165 (43): 2971. Newsroom DGK,
Cardio News 2020; 23 (11/12): 42–43.]
Associate University of Technology Sydney (UTS)
2017 – 2020
Graduate School of Health
Best Poster Award
2017
46th Symposium, European Society of Clinical Pharmacy (ESCP)
Honorary
Member
2017
Pharmaceutical Care Network Europe (PCNE)
Poster Award
2016
FIP Community Pharmacy Section
Fellow of the ESCP (FESCP)
2013
European Society of Clinical Pharmacy
(ESCP)
Lesmueller-Lecture
2013
Lesmueller Foundation, Munich
Distinguished Practice Award
2013
International Pharmaceutical Federation (FIP)
Best Poster
Award
2011
7th Pharmaceutical Care Network Europe (PCNE) Working Conference
Fellow of the FIP (FFIP)
2009
International Pharmaceutical Federation (FIP)
Poster
Award
2009
Community Pharmacy Section, FIP
Best Poster
Award
2008
33rd Scientific Congress, German Society of Hospital Pharmacists (ADKA)
IMS Health and FIP
Prize
2005
International Pharmaceutical
Federation (FIP)
Health Base Foundation
Award
1999
European Society of Clinical Pharmacy (ESCP)
PROFESSIONAL ORGANIZATIONS (MEMBER)
1. German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
2. German Pharmaceutical Society (DPhG)
3. German Society of Toxicological and Forensic Chemistry (GTFCh)
4. International Pharmaceutical Federation (FIP)
5. American Society for Clinical Pharmacology and Therapeutics (ASCPT)
6. American College of Clinical Pharmacology (ACCP)
7. American College of Clinical Pharmacy (ACCP)
8. European Society of Clinical Pharmacy (ESCP)
9. German Network Evidence-based Medicine (DNEbM)
10. German Diabetes Society (DDG)
11. International Society for Pharmacoepidemiology (ISPE)
12. International Society of Pharmacovigilance (ISoP)
13. German Cardiac Society (DGK)
14. European Society of Cardiology (ESC)
15. Cochrane Collaboration
16. American Heart Association (AHA)
17. Heart Failure Association (HFA) of the ESC
PROFESSIONAL SERVICES, COMMITTEE MEMBERSHIPS AND OTHER ACTIVITIES
ACCP/ESCP-Conferences on Clinical Pharmacy, Member, Scientific Committees
Berlin, DE (1999), Amsterdam, NL (2005), Orlando, FL, USA (2009), and Heidelberg, DE (2017).
Action Plan for Medication Safety (AMTS) in Germany Federal Ministry of Health (BMG), Berlin,
member managing committee, 2008 – present.
Member Congress Advisory Board 2nd Global Patient Safety Action Summit 2017.
Bonn, 29-30 March 2017 (Federal Ministry of Health).
Book-Reviewer for British Medical Journal, PHARMAZIE, Pharm. Ztg., Pharm. Ztg. Wiss., and PZ Prisma.
Dr. Hellmuth-Haeussermann Foundation / Award
Member Jury (Board of Trustees), 2006 – 2020.
EADV - Founding member (2000) and Vice-Chair (– present) of
the German Diabetes Society (DDG) / Federal Chamber
of Pharmacists’ (BAK) Joint Commission on the Role and Involvement of Pharmacists in the Care of Diabetic
Patients.
Editorial / Scientific Boards
Pharmacy Practice, 2006 – present.
Journal of Research in Pharmacy Practice, 2011 – present.
Pharmacoepidemiology and Drug Safety, 2017 – present.
Annals of Pharmacotherapy, 2003 – 2013.
DRUGDEX®; Micromedex, Inc., 1998 – 2010.
Pharmazeutische Zeitung Wissenschaft (Pharmaceutical Journal – Scientific Edition), 1989 – 1993.
European Association of Faculties of Pharmacy (EAFP)
Member Task Force Pharmaceutical Care, 1997 – 2000.
European Generic and Biosimilar Medicines Association (EGA)
Chair “European policy towards generic medicines”, Member Advisory Board, 2011 – 2016.
European Society of Clinical Pharmacy (ESCP)
Member of the Board (General Committee), 2006 – 2012; Member of the Research Committee, 2006 – 2017.
Federal Chamber of Pharmacists (BAK), Berlin
Member Expert Committees Post-graduate Specialization: Drug Information (2002 – present) and
Toxicology (2002 – 2020).
Federal Institute for Drugs and Medical Devices (BfArM), Bonn, voting member
- Commission on Processing Drugs in Neurology/Psychiatry
(Aufbereitungskommission B3), 1989 – 1995.
- Commission/Expert Advisory Committee on Pharmacy-only Drugs
(Sachverständigenausschuss für Apothekenpflicht), 1989 – present.
- Commission/Expert Advisory Committee on Prescription-only Drugs
(Sachverständigenausschuss für Verschreibungspflicht), 2009 – present.
- Committee on Pharmacology at the Commission for the German Pharmacopeia
(Ausschuss für Pharmakologie der Deutschen Arzneibuch-Kommission), 2000 – present.
Advisory Council on Drug Shortages § 52b (3b) AMG
(BMG/BfArM), member
German Institute of Medical Documentation and Information (DIMDI), Bonn:
Member Board of Trustees Health Technology Assessment (HTA), 2008 – 2011.
GKV-Arzneimittelindex (Statutory Health Insurance Drug Index), Berlin:
Member Advisory Board, 2009 – present.
Clinical Practice Guideline Committees – voting member
· National Disease Management-/Clinical Practice Guidelines (Nationale VersorgungsLeitlinie [NVL])
· Asthma (2nd ed. 2008, 3rd ed. 2018, 4th ed. 2020)
· Chronic Heart Failure (2nd ed. 2017, 3rd ed. 2019; amendment 2021)
· COPD (2nd ed. 2020/2021)
· Diabetes (1st comprehensive ed. 2020/2021)
· S3 Guideline: Drug-related disorders (2021)
Institute for Quality and Efficiency in Health Care (IQWiG), Cologne
Member Board of Trustees (HTA), 2008 – present.
International Pharmaceutical Federation (FIP)
Planning Committee Continuing Education Programme/Continuing Professional Development of the Community Pharmacy Section (CPS), 1993 –
2007;
Board of Pharmaceutical Practice (BPP): Expert Member (2006 – 2013), Member Programme Committee (2002 – 2006), and Chairman Programme Committee (2006 – 2011);
Co-Chair FIP Centennial Programme Committee (2010 – 2012);
Board of Pharmaceutical Sciences (BPS): Vice-chair SIG Pharmacy Practice Research (2016 – 2019).
Peer Reviewer for (in the order of IF): British Medical Journal, European Heart Journal, European Journal of Heart Failure, Thorax, Cochrane Database of Systematic Reviews, Clinical Pharmacology & Therapeutics, Clinical Research in Cardiology, Journal of the American Heart Association, Frontiers in Pharmacology, ESC Heart Failure, Preventive Medicine, British Journal of Clinical
Pharmacology, Toxicology, International Journal of Chronic Obstructive Pulmonary Disease, Pharmacotherapy, Drug Safety, International Journal of Cardiology, PLoS ONE, Pharmacoepidemiology and
Drug Safety, Research in Social and Administrative Pharmacy, Journal of Clinical Hypertension, European Journal of Clinical Pharmacology, American Journal of Cardiovascular Drugs, BMJ Open,
Journal of Clinical Pharmacology, Annals of Pharmacotherapy, Journal of Human Hypertension, Clinical Interventions in Aging, European Journal of Health Economics, Health Policy, Pharmacopsychiatry, International Journal for Quality in Health Care,
Journal of Health Services Research & Policy, Patient Preference and Adherence, International Journal of General Medicine, International Journal of Behavioral Medicine, BMC Family Practice,
International Journal of Clinical Pharmacy, Journal of the American Pharmaceutical Association, Die PHARMAZIE, European Journal of Hospital Pharmacy, Das Gesundheitswesen, Journal of Integrated
Pharmacy Research and Practice, ClinicoEconomics and Outcomes Research, International Journal of Pharmacy Practice, Current Drug Safety, Journal of Pharmacy Technology, and GaBI
Journal.
Pharmaceutical Care Foundation (FI), Berlin
Member Scientific Board; 1998 – 2006 and 2011 – present.
Pharmaceutical Care Network Europe (PCNE)
Founding member, 1994; chairman, 1999 – 2001; member of the board, 1999 – 2005; Honorary Member, 2017.
Task Force "Lunapharm"
Ministry of Health, Federal State of Brandenburg; member, 2018.
World Health Organization (WHO)
Review Committee for Reports on Pharmaceutical
Matters, member, 1989 – 1994.
PUBLICATIONS
Over 550 articles (full
lists); h-index: 30, citations 4843, i10-index: 64.
List of selected peer reviewed
publications
1. Schulz, M. and
Schmoldt, A.:
INTERACTIONS OF THE HISTAMINE H2-RECEPTOR ANTAGONIST ETINTIDINE WITH RAT
LIVER CYTOCHROME P-450: A COMPARISON WITH CIMETIDINE.
Naunyn-Schmiedeberg's Arch. Pharmacol. 1987; 336 (4): 453–458.
PubMed
2. Frese, J.H., Rohland, L., Schulz, M. and
Schmoldt, A.:
INTOXIKATION MIT GALLOPAMIL. Verlauf und Therapie.
Dtsch. Med. Wochenschr. 1998; 113 (19): 770–772.
PubMed
3. Schulz, M.:
INTERAKTIONEN AUSGEWÄHLTER HISTAMIN H2-REZEPTORANTAGONISTEN MIT DEM
CYTOCHROM P-450-SYSTEM UND MÖGLICHE AUSWIRKUNGEN AUF DIE PHARMAKO-
KINETIK NICHTSTEROIDALER ANTIRHEUMATIKA
[Interactions of selected histamine H2-receptor antagonists with
the cytochrome P-450 system and potential effects on the pharmacokinetics of non-steroidal antiinflammatory drugs].
Dissertation Dr. rer. nat. (PhD thesis),
University of Hamburg 1988.
4. Schulz, M.,
Schmoldt, A., Donn, F. and Becker, H.:
THE PHARMACOKINETICS OF FLUTAMIDE AND ITS MAJOR METABOLITES AFTER A SINGLE ORAL DOSE AND DURING CHRONIC
TREATMENT.
Eur. J. Clin. Pharmacol. 1988; 34 (6): 633–636.
PubMed
5. Schulz, M. and
Schmoldt, A.:
ON THE SULPHOXIDATION OF CIMETIDINE AND ETINTIDINE BY RAT AND HUMAN LIVER MICROSOMES.
Xenobiotica 1988; 18
(8): 983–989.
PubMed
6. Donn, F., Bruns, T., von
Meyerinck, L., Schulz, M., Becker, W.-M., Becker, H. and
Klosterhalfen, H.:
MONOCLONAL ANTIBODY THAT DEFINES THE PROSTATE SPECIFIC ANTIGEN.
Prostate 1989; 14 (3): 237–249.
PubMed
7. Schulz, M. and Schmoldt, A.:
DETERMINATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN HUMAN PLASMA
BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.
Pharm. Ztg. Wiss. 1989; 134 (2): 41–44.
8. Schulz, M., Wischhusen, F. and Schmoldt,
A.:
THERAPEUTISCHE UND TOXISCHE PLASMAKONZENTRATIONEN SOWIE ELIMINATIONSHALBWERTSZEITEN GEBRÄUCHLICHER ARZNEISTOFFE.
Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 1991; 26 (1): 37–43.
PubMed
Schulz, M. and Schmoldt, A.:
as extended version in: Pharm. Ztg. Wiss. 1991; 136 (4): 87–94.
9. Schulz, M. and Schmoldt, A.:
KONZENTRATIONEN VON CEFOTIAM IM KOLONGEWEBE UND PLASMA NACH APPLIKATION ZUR PERIOPERATIVEN ANTIBIOTIKA-PROPHYLAXE
[Concentrations of cefotiam in colon tissue and plasma after application for perioperative antibiotic prophylaxis].
Zeitschr. Antimikrobiol. Antineoplast. Chemother. 1992; 10: 33–37.
10. Schulz, M. and Schmoldt,
A.:
NON-INTERACTION OF RANITIDINE WITH HYDROXYLATION OF DICLOFENAC IN RAT AND HUMAN LIVER MICROSOMES.
Pharmazie 1993; 48 (8): 625–626.
PubMed
11. Schulz, M. and Schmoldt,
A.:
SUCCESSFUL PHYSOSTIGMINE TREATMENT OF ACUTE DOTHIEPIN INTOXICATION.
Pharmazie 1994; 49 (8):
614.
PubMed
12. Scholz, J., Bause, H., Schulz,
M., Klotz, U., Krishna, D.R., Pohl, S. and Schulte am Esch, J.:
PHARMACOKINETICS AND EFFECTS ON INTRACRANIAL PRESSURE OF SUFENTANIL IN HEAD TRAUMA PATIENTS.
Br. J. Clin.
Pharmacol. 1994; 38 (4): 369–372.
PubMed
13. Schulz, M. and Schmoldt, A.:
ZUSAMMENSTELLUNG THERAPEUTISCHER UND TOXISCHER
PLASMAKONZENTRATIONSBEREICHE VON ARZNEISTOFFEN.
Anaesthesist 1994; 43 (12): 835–844.
PubMed
14. Scholz, J., Schulz, M.,
Steinfath, M., Höver, S. and Bause, H.:
FLUCONAZOLE IS REMOVED BY CONTINUOUS VENOVENOUS HEMOFILTRATION IN A
LIVER TRANSPLANT PATIENT.
J. Mol. Med. 1995; 73 (3): 145–147.
PubMed
15. Schmoldt, A., Sagowski, C., Iwersen, S., and
Schulz, M.:
HEMMUNG DER ADH-AKTIVITÄT DES MAGENS DURCH H2-REZEPTORENBLOCKER
[Inhibition of gastric alcohol dehydrogenase activity by histamine H2-receptor antagonists].
Rechtsmedizin 1995; 5: 73–77.
16. Fox, J.M., with contribution of
Menges, K., Coper, H., Doenicke, A., Ferner, U.J., Gaertner, H.J., Hoffmeister, F., Janke, W., Janzen, R.W.C., Kanowski, S., Kreiskott, H., Müller-Oerlinghausen, B., Netter, P., Oelschläger, H.,
Poser, W., Radke, J., Rüther, E. and Schulz, M.:
KOMBINATIONSARZNEIMITTEL AUS PARACETAMOL PLUS ACETYLSALICYLSÄURE: NUTZEN UND RISIKEN
[Fixed-dosed combinations of paracetamol(acetaminophen) and aspirin: benefits and risks].
Schmerz 1995; 9:
273–285.
17. Scholz, J., Steinfath, M. and
Schulz, M.:
CLINICAL PHARMACOKINETICS OF ALFENTANIL, FENTANYL, AND SUFENTANIL:
AN UPDATE.
Clin. Pharmacokinet. 1996; 31 (4): 275–292.
PubMed
18. Schulz, M. and Schmoldt,
A.:
THERAPEUTIC AND TOXIC BLOOD CONCENTRATIONS OF MORE THAN 500 DRUGS.
Pharmazie 1997; 52 (12):
895–911.
PubMed
19. Iwersen-Bergmann, S., Schmoldt, A., Püschel, K. and Schulz,
M.:
VERGIFTUNGS- UND TODESFÄLLE DURCH SUBSTITUTIONSMITTEL IM UMFELD VON SUBSTITUIERTEN DROGENKONSUMENTEN.
Rechtsmedizin 1999; 9 (3): 90–93.
Abstract
20. Stein, S., Schmoldt, A. and Schulz, M.:
FATAL INTOXICATION WITH MELPERONE.
Forensic Sci. Int. 2000; 113 (1-3): 409–413.
PubMed
21. Seibt, K., Schulz, M. and Hensel, F.J.:
MEINUNGEN UND EINSTELLUNGEN ZUM THEMA IMPFEN BEI NIEDERGELASSENEN ÄRZTEN, OFFIZINAPOTHEKERN UND IHREM PERSONAL SOWIE AKTUELLER IMPFSTATUS DIESER GRUPPEN
[Opinions and attitudes on the topic of vaccination of established physicians, pharmacists and their personnel and current vaccination status of these
groups].
Gesundheitswesen 2000; 62 (7): 376–382.
PubMed
22. Schulz, M., Schmoldt, A., Donn, F. and Becker, H.:
LACK OF METHEMOGLOBINEMIA WITH FLUTAMIDE.
Ann. Pharmacother. 2001; 35 (1): 21–25.
PubMed
23. Brockmeyer, R.,
Steindl, L., Behrens, I., Gnekow, S., Verheyen, F. and Schulz, M.:
Testing of the readability of package inserts at a community pharmacy.
Pharm. Ind. 2001;
63 (2): 114–119.
24. Schulz, M., Verheyen, F., Mühlig, S., Müller, J.M., Mühlbauer, K., Knop-Schneickert, E., Petermann, F. and Bergmann, K.-C.:
PHARMACEUTICAL CARE SERVICES FOR ASTHMA PATIENTS.
A CONTROLLED INTERVENTION STUDY.
J. Clin. Pharmacol. 2001; 41 (6): 668–676.
PubMed
25. Azodi, K., Himstedt, S.,
Hinrichs, A., Krüger, M., Schrader, S. and Schulz, M.:
TESTING OF THE READABILITY OF PACKAGE LEAFLETS AS AN INITIAL STEP UNDER THE PHARMACEUTICAL CARE INITIATIVE TOWARDS INCREASING THE SAFETY OF MEDICINAL PRODUTCS.
Pharm. Ind. 2002; 64 (11): 1119–1125.
26. Hauner, H., Maxion-Bergemann, S., Müller, E., Schulz,
M., Huppertz, E. and Bergemann, R.:
DMP DIABETES MELLITUS: SIMULATION DER BEHANDLUNGSERGEBNISSE VERSCHIEDENER LEITLINIEN. Ein neues Diabetes
mellitus Modell (DMM).
[Disease management program (DMP) diabetes mellitus: simulation of therapeutic
results of different guidelines. A new diabetes mellitus model (DMM)].
Dtsch. Med. Wochenschr. 2003; 128 (21): 1167–1172.
PubMed
27. Schulz, M. and Schmoldt,
A.:
THERAPEUTIC AND TOXIC BLOOD CONCENTRATIONS OF MORE THAN 800 DRUGS AND OTHER XENOBIOTICS.
Pharmazie 2003; 58 (7):
447–474.
PubMed
28. Van Mil, J.W.F., Schulz,
M. and Tromp, Th.F.J.:
PHARMACEUTICAL CARE, EUROPEAN DEVELOPMENTS IN CONCEPTS, IMPLEMENTATION, TEACHING, AND RESEARCH: A REVIEW.
Pharm. World Sci. 2004; 26 (6): 303–311.
PubMed
29. Berger, K, Eickhoff, C. and
Schulz, M.:
Counselling quality in community pharmacies:
Implementation of the pseudo customer methodology in Germany.
J. Clin. Pharm. Ther. 2005; 30 (1): 45–57.
PubMed
30. Mangiapane, S., Schulz,
M., Mühlig, S., Ihle, P., Schubert, I. and Waldmann, H.-C.:
COMMUNITY PHARMACY-BASED PHARMACEUTICAL CARE FOR ASTHMA PATIENTS.
Ann. Pharmacother. 2005; 39 (11): 1817–1822.
PubMed
31. Eickhoff, C. and Schulz,
M.:
PHARMACEUTICAL CARE IN COMMUNITY PHARMACIES: PRACTICE AND RESEARCH IN GERMANY.
Ann. Pharmacother. 2006; 40 (4): 729–735.
PubMed
32. Schulz, M., Graefe, T.,
Stuby, K., Andresen, H., Kupfermann, N. and Schmoldt, A.:
Case report: Acute unintentional carbachol intoxication.
Critical Care 2006; 10: R84.
Full text
33. Schulz, M., Hämmerlein,
A., Hinkel, U., Weis, G. and Gillissen, A.:
SAFETY AND USAGE PATTERN OF AN OVER-THE-COUNTER AMBROXOL COUGH SYRUP:
A COMMUNITY PHARMACY-BASED COHORT STUDY.
Int. J. Clin. Pharmacol. Ther. 2006; 44 (9): 409–421.
PubMed
34. Müller, U., Hämmerlein, A., Casper, A. and Schulz,
M.:
EVALUATION DER DURCHFÜHRUNG VON GLUKOSESELBSTKONTROLLEN IN APOTHEKEN (EDGAr).
Diabetes Stoffw. Herz 2006;
15 (4): 9–17.
COMMUNITY PHARMACY-BASED INTERVENTION TO IMPROVE SELF-MONITORING OF BLOOD GLUCOSE IN TYPE 2
DIABETIC PATIENTS.
Pharmacy Practice 2006; 4 (4): 195–203.
Full text
35. Schuessel, K. and Schulz,
M.:
PRESCRIBING OF COX-2-INHIBITORS IN GERMANY AFTER SAFETY WARNINGS AND MARKET WITHDRAWALS.
Pharmazie 2006; 61
(10): 878–886.
PubMed
36. Van Mil, J.W.F. and Schulz, M.:
A review of Pharmaceutical Care in Community Pharmacy in Europe.
Harvard Health Policy Review 2006; 7 (1): 155–168.
Full
text
37. Gerdemann, A., Griese, N. and Schulz, M.:
PHARMACY INTERNS ON THE WARD – A PILOT STUDY.
Pharm. World Sci. 2007; 29 (1): 34–38.
PubMed
38. Rajska-Neumann, A.,
Wieczorowska-Tobis, K., Schulz, M., Breborowicz, A., Grzeskowiak, E. and Oreopoulos D.G.:
Duplicate use of angiotensin-converting enzyme (ACE) inhibitors in a community-dwelling elderly population in Poland.
Arch. Gerontol. Geriatr. 2007; 44 (Suppl. 1): 295–301.
PubMed
39. Bertsche, T., Hämmerlein, A. and Schulz, M.:
GERMAN NATIONAL DRUG INFORMATION SERVICE: USER SATISFACTION AND POTENTIAL POSITIVE PATIENT OUTCOMES.
Pharm. World. Sci. 2007; 29 (3): 167–172.
PubMed
40. Hämmerlein, A., Griese, N., and
Schulz, M.:
Survey of Drug-related Problems Identified by Community
Pharmacies.
Ann. Pharmacother. 2007; 41 (11): 1825–1832.
PubMed
41. Schüssel, K., Quinzler, R., Czeche, S. and Schulz, M.:
AKTUELLE VEORDNUNGEN VON COX-2-HEMMERN IN DEUTSCHLAND
[Contemporary precriptions of COX-2 inhibitors in Germany].
Internist. Praxis 2008; 48 (4): 837–850.
42. Hämmerlein, A. and Schulz, M.:
Co-authors of the German National Disease Management Guideline (Nationale VersorgungsLeitlinie (NVL)) ASTHMA, 2nd ed. 2009.
Eds.: Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung
(KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF).
Revision in: Dtsch. Ärztebl. 2011; 108 (11): A-596 / B-484 / C-484.
Guideline
43. Hämmerlein, A., Müller, U. and Schulz, M.:
VERSORGUNGSMANAGEMENT FÜR MENSCHEN MIT ASTHMA – EINBINDUNG DER APOTHEKER
[Involving pharmacists in the management of asthma
patients].
Z. Evid. Fortbild. Qual. Gesundh. wesen 2010; 104 (2): 92–98.
44. Hämmerlein, A., Müller, U. and
Schulz M.:
Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients.
J. Eval. Clin. Pract. 2011; 17 (1): 61–70.
PubMed
45. Krüger, M., Griese, N. and Schulz, M.:
Medikationsmanagement für Menschen mit Diabetes.
[Home medication review for
patients with diabetes].
Diabetes Stoffw. Herz 2011; 20 (4): 219–226.
Abstract
46. Hohmann, C., Eickhoff, C., Kämmerer, W. and Schulz, M.:
Compliance with antithrombotic guidelines in surgery patients in German hospitals: A multicenter study involving pharmacy interns.
Clin. Appl. Thromb. Hemost. 2012; 18 (3): 299–304.
PubMed
47. Ude, M., Schüssel. K., Quinzler, R., Leuner,
K., Müller, W.E. and Schulz, M.:
Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a
retrospective Study using the DAPI database.
J. Hypertens. 2011; 29 (9): 1837–1845.
PubMed
48. Hohmann, C. Eickhoff, C., Klotz,
J.M., Schulz, M. and Radziwill, R.:
DEVELOPMENT OF A CLASSIFICATION SYSTEM FOR DRUG-RELATED PROBLEMS IN THE HOSPITAL SETTING (APS-Doc) AND ASSESSMENT OF THE INTER-RATER RELIABILITY.
J. Clin. Pharm. Ther. 2012; 37 (3): 276–281.
PubMed
49. Laufs, U., Böhm, M., Kroemer, H.K., Schüssel, K., Griese, N. and Schulz, M.:
Strategien zur Verbesserung der Einnahmetreue von Medikamenten
[Strategies to improve medication adherence].
Dtsch. Med. Wochenschr. 2011; 136 (31-32): 1616–1621.
PubMed
50. Quinzler, R., Ude, M.,
Franzmann, A., Feldt, S., Schüssel, K., Leuner, K., Müller,
W.E., Dippel.F.-W. and Schulz, M.:
Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in type 2 diabetic patients: comparison of insulin glargine with NPH
insulin.
Int. J. Clin. Pharmacol. Ther. 2012; 50 (1): 24–32.
PubMed
51. Eickhoff, C., Hämmerlein, A.,
Griese, N. and Schulz, M.:
Nature and frequency of drug-related problems in self-medicatioN (OVER-THE-COUNTER DRUGS) in daily community pharmacy practice in Germany.
Pharmacoepidemiol. Drug Saf. 2012; 21 (3); 254-260.
PubMed
52. Hohmann, C., Eickhoff, C., Radziwill, R. and Schulz, M.:
Adherence to guidelines for antibiotic prophylaxis in surgery patients in German hospitals: A multicenter evaluation involving pharmacy
interns.
Infection 2012; 40 (2): 131–137.
PubMed
53. Feldt, S., Schüssel, K., Quinzler, R., Franzmann, A., Czeche, S., Ludwig, W.-D. and Schulz, M.:
INCIDENCE OF THYROID HORMONE THERAPY IN PATIENTS TREATED WITH SUNITINIB OR SORAFENIB: A COHORT STUDY.
Eur. J. Cancer 2012; 48 (7): 974-981.
PubMed
54. Schulz, M.,
Iwersen-Bergmann, S., Andresen, H. and Schmoldt, A.:
THERAPEUTIC AND TOXIC BLOOD CONCENTRATIONS OF NEARLY
1,000 DRUGS AND OTHER XENOBIOTICS.
Critical Care 2012; 16: R136. [>21k accesses].
Full text incl. suppl. material Additional file 1
55. Ude, M., Leuner, K., Schüssel, K., Schulz, M. and Müller, W.E.:
ADHERENCE TO ANTIHYPERTENSIVES: FEASIBILITY OF TWO SELF-REPORT INSTRUMENTS TO INVESTIGATE MEDICATION-TAKING BEHAVIOUR IN GERMAN COMMUNITY PHARMACIES.
Int. J. Pharm. Pract. 2013; 21 (3): 169-177.
PubMed
56. Nicolas, A., Eickhoff, C., Griese, N. and Schulz, M.:
drug-related problems in prescribed medicines IN GermanY at the time OF dispensING.
Int. J. Clin. Pharm. 2013; 35 (3): 476-482.
PubMed
57. Czeche, S., Schüssel, K., Franzmann, A., Burkart, M. and Schulz, M.:
DOSAGE STRENGTH IS ASSOCIATED WITH MEDICATION PERSISTENCE WITH GINGKO BILOBA DRUG PRODUCTS.
BMC Complement. Altern. Med. 2013; 13 (1): 278.
Full text
PDF
58. Saverno, K., Gothe, H.,
Schüssel, K., Biskupiak, J.E., Schulz, M., Siebert, U. and Brixner, D.:
Consideration of International Generic Distribution Policies on Patient Outcomes in the United States and Germany.
Pharmazie 2014; 69 (3): 238-240.
PubMed
59. Schorr, S.G., Eickhoff, C.,
Feldt, S., Hohmann, C. and Schulz, M.:
EXPLORING THE potential impact of hospital ward-based pharmacy interns on drug safety.
Pharmazie 2014; 69 (4): 316-320.
PubMed
60. Ewen, S., Baumgarten, T., Rettig-Ewen,
V., Mahfoud, F., Griese-Mammen, N., Schulz, M., Böhm, M. and Laufs, U.:
Analyses of drugs stored at home by elderly patients with chronic heart failure.
Clin. Res. Cardiol. 2015; 104 (4): 320-327.
PubMed
61. Fikenzer, K., Knoll, A., Fischer, D.,
Schulz, M., Böhm, M. and Laufs, U.:
Chronische Herzinsuffizienz: Teufelskreis aus geringer
Einnahmetreue von Medikamenten und kardialer Dekompensation.
[Poor medication adherence and worsening heart failure - a vicious circle].
Dtsch. Med. Wochenschr.
2014; 139 (47): 2390-2394.
PubMed
62. Krueger, K., Botermann, L., Schorr, S.G., Griese-Mammen, N., Laufs,
U. and Schulz, M.:
Age-related medication adherence in patients with chronic heart failure: a systematic literature review.
Int. J. Cardiol. 2015; 184: 728-735.
PubMed
63. Schulz, M., Meins, J.,
Diemert, S., Zagermann-Muncke, P., Goebel, R., Schrenk, D., Schubert-Zsilavecz, M. and Abdel-Tawab, M.:
Detection of pyrrolizidine alkaloids in German licensed herbal medicinal teas.
Phytomedicine. 2015; 22 (6): 648-656.
PubMed
ScienceDirect
64. Hansen, K., Schüssel, K., Kieble, M., Werning, J., Schulz,
M., Friis, R., Pöhlau, D., Schmitz, N. and Kugler, J.:
Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: A retrospective cohort
study.
PLoS One 2015; 10 (7): e0133279.
Full
text
65. van Mil, J.W.F., Westerlund, T., Brown, L., Chen, T.F., Henman, M., Hersberger, K., McElnay, J. and Schulz, M.:
Medical care and Drug-related problems: Do doctors and pharmacists speak the same language?
Int. J. Clin. Pharm. 2016; 38 (2): 191–194, erratum 195.
PubMed Erratum
66. Botermann, L., Krueger, K., Eickhoff, C., Kloft, C. and Schulz, M.:
PATIENT’S HANDLING OF A STANDARDIZED MEDICATION PLAN: A PILOT STUDY
AND METHOD DEVELOPMENT.
Patient Prefer. Adherence 2016; 10: 621–630.
Full
text
67.
Botermann, L., Monzel, K., Krueger, K., Eickhoff, C., Wachter, A., Kloft,
C., Laufs, U. and Schulz, M.:
EVALUATING PATIENTS’ COMPREHENSIBILITY OF A STANDARDIZED MEDICATION PLAN.
Eur. J. Clin. Pharmacol. 2016; 72 (10):
1229–1237.
PubMed EJCP
68.
Schulz, M., Krueger, K., Schuessel, K., Friedland, K., Laufs, U.,
Müller, W.E. and Ude, M.:
MEDICATION ADHERENCE AND Persistence according to DIFFERENT antihypertensive drug classES: A RETROSPECTIVE cohort STUDY of 255,500 patients.
Int. J. Cardiol. 2016; 220: 668–676.
PubMed IJC Full
text
69. Ganso, M., Goebel, R., Melhorn, S., Schrenk, D. and Schulz, M.:
Lipidpneumonie durch LIPID-haltige Nasensprays und -tropfen
[Lipoid pneumonia associated with lipid-containing nasal sprays and
nose drops].
Laryngo-Rhino-Otol. 2016; 95 (8): 534–539.
PubMed
70. Gradl, G., Krieg, E.-M. and Schulz, M.:
EVALUATION OF PHARMACEUTICAL CONCERNS IN GERMANY: FREQUENCY AND POTENTIAL REASONS.
Pharm. Pract. 2016; 14 (3): 786.
PubMed Full text Suppl. material
71. Schulz, M., Goebel, R., Schumann, C. and
Zagermann-Muncke, P.:
Non-prescription dispensing of emergency oral contraceptives: Recommendations from the German Federal Chamber of Pharmacists
[Bundesapothekerkammer].
Pharm. Pract. 2016; 14 (3): 828.
PubMed Full
text
72. Custodis, F., Rohlehr, F., Wachter, A., Böhm, M., Schulz, M. and Laufs, U.:
Medication knowledge of patients hospitalized for heart failure at admission and after discharge.
Patient Prefer. Adherence 2016;
10: 2333–2339.
PubMed
73. Krueger,
K., Griese-Mammen, N., Schubert, I., Kieble, M., Botermann, L., Laufs, U., Kloft, C. and Schulz, M.:
IN
SEARCH OF A STANDARD WHEN ANALYZING MEDICATION ADHERENCE IN PATIENTS WITH HEART FAILURE USING CLAIMS DATA: A SYSTEMATIC REVIEW.
Heart
Fail. Rev. 2018; 23 (1):
63–71.
74. Botermann,
L., Wachter, A., Monzel, K., Krueger, K., Ewen, S., Mahfoud, F., Griese-Mammen, N., Schulz,
M. and Laufs, U.:
DO PATIENTS WITH DIABETES TYPE 2 OR CHRONIC HEART FAILURE UNDERSTAND A MEDICATION PLAN?
Pharmazie 2017; 72 (12):
764–768.
PubMed
75. Felberg, M., Reckers, K., Schulz,
M. and Scherneck, S.:
DER DIABETOLOGISCH
QUALIFIZIERTE APOTHEKER DDG. EVALUATION EINER PRAXISORIENTIERTEN INTENSIV-FORTBILDUNG
[Community pharmacist care of patients with diabetes: opportunities and limitations].
Med. Monatsschr.
Pharm. 2017; 40 (11): 496–501.
76. Weißenborn, M., Schulz,
M., Kraft, M., Haefeli, W.E. and Seidling, H.M.:
POTENTIELLE
ERFOLGSINDIKATOREN FÜR DIE DURCHFÜHRUNG VON PROJEKTEN ZUR ARZT-
APOTHEKER-ZUSAMMENARBEIT – EINE SYSTEMATISCHE ÜBERSICHT
[Potential benchmarks for successful interdisciplinary collaboration projects in Germany – A systematic review].
Gesundheitswesen 2019; 81
(12): 1057–1068. Epub
June 21, 2018.
77.
Laufs, U., Griese-Mammen, N., Krueger, K., Wachter, A., Anker, S.D.,
Koehler, F., Rettig-Ewen, V.,
Botermann, L., Strauch, D., Trenk, D., Böhm, M. and Schulz, M.:
PHARMACY-BASED INTERDISCIPLINARY PROGRAM FOR PATIENTS WITH CHRONIC HEART
FAILURE (PHARM-CHF): RATIONALE
AND DESIGN OF A RANDOMIZED CONTROLLED TRIAL AND RESULTS OF THE PILOT STUDY.
Eur. J. Heart Fail.
2018; 20 (9): 1350–1359.
78. Dormann, H., Maas, R., Eickhoff, C., Müller, U., Schulz, M., Brell, D. and Thürmann, P.:
ERPROBUNG DES BUNDESEINHEITLICHEN MedikationsplanS IN DER PRAXIS: Die Pilotprojekte MetropolMediplan 2016, Modellregion Erfurt und PRIMA
[Testing the standardized medication plan: the pilot projects MetropolMediplan 2016, model region Erfurt and PRIMA].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61 (9): 1093–1102.
79. Müller, U., Schulz, M. and Mätzler, M.:
Elektronisch unterstützte Kooperation ambulant tätiger Ärzte und Apotheker zur Verbesserung der Arzneimitteltherapiesicherheit. Die
Arzneimittelinitiative Sachsen-Thüringen (ARMIN)
[Electronically supported co-operation of physicians and pharmacists to improve medication safety in the ambulatory setting. The “Arzneimittelinititative Sachsen-Thüringen” (ARMIN)].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61 (9): 1119–1128.
80. Gradl, G., Teichert, M., Kieble, M., Werning, J. and Schulz, M.:
COMPARING OUTPATIENT ORAL ANTIBIOTIC USE IN GERMANY AND THE NETHERLANDS FROM 2012 TO 2016.
Pharmacoepidemiol. Drug Saf. 2018; 27 (12):
1344–1355.
Full text
81. Said, A., Goebel, R., Ganso, M., Zagermann-Muncke, P. and Schulz,
M.:
Drug shortages may compromise patient safety: results of a survey of the
reference pharmacies of the Drug Commission of German Pharmacists.
Health Policy. 2018; 122 (12):1302–1309.
PubMed
82. Katzman, J., Mahfoud, F., Böhm, M., Schulz, M. and Laufs, U.:
Association of medication adherence and depression with control of LDL
Cholesterol and blood pressure in patients with high cardiovascular risk.
Patient Prefer. Adherence. 2019; 13: 9–19.
Full text
83. Ihle, P., Krueger, K.,
Schubert, I. Griese-Mammen, N., Parrau, N., Laufs, U. and Schulz, M.:
COMPARISON OF DIFFERENT STRATEGIES TO MEASURE MEDICATION ADHERENCE VIA CLAIMS
DATA IN PATIENTS WITH CHRONIC HEART FAILURE.
Clin. Pharmacol. Ther. 2019; 106 (1):
211–218.
Full
text
84. Breiholz, S., Griese-Mammen, N., Krueger, K., Schaefer, M. and Schulz, M.:
Acceptance of a Medication Refill Reminder Service in GERMAN Community Pharmacy
Practice.
Pharmazie 2019; 74 (3): 186–190.
PubMed
85. Eickhoff, C., Müller, U., Strunz, A.K., Seidling, H.M., Lampert, A., Felberg,
M., Breiholz, S., Klintworth, D. and Schulz, M.:
Das Projekt PRIMA - Elektronische Erstellung und Aktualisierung von Medikationsplänen als gemeinsame Aufgabe
von Ärzten
und Apothekern
[The PRIMA project -
electronically-supported physician-pharmacist co-operation to generate and update medication plans
in Germany].
Dtsch. Med. Wochenschr. 2019; 144 (18): e114–e120.
Full text
86. Schulz, M., Griese-Mammen, N., Anker, S.D., Koehler, F., Ihle, P., Ruckes, C., Schumacher, P.M., Trenk, D., Böhm, M. and
Laufs, U.:
PHARMACY-BASED INTERDISCIPLINARY INTERVENTION FOR PATIENTS WITH CHRONIC HEART
FAILURE: RESULTS OF THE PHARM-CHF RANDOMIZED CONTROLLED TRIAL.
Eur. J. Heart Fail. 2019; 21 (8):
1012–1021.
Full text Suppl.
Material
87. Hofmann, G. A., Gradl, G., Schulz, M., Haidinger, G., Tanew, A. and Weber, B.:
THE FREQUENCY OF PHOTOSENSITIZING
DRUG DISPENSINGS IN AUSTRIA AND GERMANY: A
CORRELATION WITH THEIR PHOTOSENSITIZING POTENTIAL BASED ON PUBLISHED LITERATURE.
J. Eur. Acad. Dermatol. Venereol. 2020; 34 (3):
589–600.
88. Said,
A., Ganso, M., Freudewald, L. and Schulz, M.:
TRENDS IN DISPENSING ORAL EMERGENCY CONTRACEPTIVES AND SAFETY ISSUES:
A SURVEY OF GERMAN COMMUNITY PHARMACISTS.
Int. J. Clin. Pharm. 2019; 41 (6): 1499–1506.
IJCP PDF Suppl. Material
89. Schönfeld, T., Heineman, A., Schulz, M., Gradl, G., Andresen-Streichert, H.,
Müller, A. and Iwersen-Bergmann, S.:
POST-MORTEM ANALYSIS OF PRESCRIPTION OPIOIDS - A FOLLOW-UP EXAMINATION BY LC-MS/MS
WITH FOCUS ON FENTANYL.
Forensic Science International.
2019; 305: 109970.
Forensic Sci Int
PubMed
90. Schulz, M.,
Schmoldt, A., Andresen-Streichert, H. and Iwersen-Bergmann, S.:
REVISITED: THERAPEUTIC AND TOXIC BLOOD CONCENTRATIONS OF MORE THAN 1,100 DRUGS
AND OTHER XENOBIOTICS.
Critical Care. 2020; 24 (1): 195.
PDF Suppl File
91. Schulz, M., Griese-Mammen,
N., Schumacher, P.M., Anker, S.D., Koehler, F., Ruckes, C., Rettig-Ewen, V., Wachter, R., Trenk, D.,
Böhm, M. and Laufs, U.:
THE IMPACT OF PHARMACIST/PHYSICIAN CARE ON QUALITY OF LIFE IN ELDERLY HEART FAILURE PATIENTS:
RESULTS OF THE PHARM-CHF RANDOMIZED CONTROLLED TRIAL.
ESC Heart Failure. 2020; 7 (6): 3310–3319.
PDF
92. Garcia
Cardenas, V., Rossing, C., Fernandez-Llimos, F., Schulz, M., Tsuyuki, R.T., Bugnon, O., Tonin, F. and Benrimoj, S.I.:
PHARMACY
PRACTICE RESEARCH – A CALL TO ACTION.
Research
in Social and Administrative Pharmacy. 2020; 16 (11): 1602–1608.
RSAP PubMed
93. Mahfoud, F., Kieble, M., Enners, S., Werning, J., Laufs, U., Millenaar, D.,
Böhm, M., Kintscher, U. and Schulz, M.:
ROTE-HAND-BRIEF ZU HYDROCHLOROTHIAZID UND VERORDNUNG VON ANTIHYPERTENSIVA
[„Dear Doctor“ warning letter (Rote-Hand-Brief) on hydrochlorothiazide and its impact on antihypertensive
prescription].
Deutsches Ärzteblatt International. 2020; 117 (41): 687–688.
PDF
94.
Schulz, M., Griese-Mammen, N., Schumacher, P.M., Strauch, D., Freudewald, L., Said,
A., Tsuyuki, R.T., Laufs, U., Kintscher, U.,
Böhm, M. and Mahfoud, F.:
Development and Implementation of Blood Pressure Screening and Referral Guidelines for German
Community Pharmacists.
Journal of Clinical Hypertension. 2020; 22 (10): 1807–1816.
PDF
95. Rudolph, U., Enners, S., Kieble, M., Mahfoud, F., Böhm, M., Laufs, U. and Schulz, M.:
IMPACT of Angiotensin Receptor Blocker Product Recalls ON ANTIHYPERTENSIVE PRESCRIBING in Germany.
Journal of Human Hypertension. 2020; [DOI: 10.1038/s41371-020-00425-z]. Epub October 14, 2020.
PDF
96. Moorkens, E., Barcina, T., Vulto, A.G., Schulz, M., Gradl, G., Enners, S., Selke, G., Huys, I. and Simoens, S.:
Learnings from
Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
Pharmaceuticals. 2020; 13 (10): 324.
PDF
97. Said, A.,
Freudewald, L., Parrau, N., Ganso, M. and Schulz, M.:
Pharmacists’ perception of educational material TO IMPROVE PATIENT SAFETY: A CROSS-SECTIONAL
sTuDy on practices and awareness IN GERMANY.
Medicine. 2021; 100 (11):
e25144.
PDF
98.
Rüsenberg, R., Baumgarten, A., Mauss, S., Gradl,
G., Schulz, M., Bartmeyer, B., Kollan, C. and Schmidt, D.:
WIE WIRKEN GENERIKAQUOTEN? EINE ANALYSE AM BEISPIEL
HIV
[How do generic quotas work? An analysis
using HIV infection as an e example].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.
2021; 64: [DOI: 10.1007/s00103-021-03312-1]. Epub April 14, 2021.
PDF
TALKS, (INVITED) LECTURES, AND PAPERS PRESENTED
Over 450 speeches, posters, and invited talks/lectures (full list).
TEXTBOOKS
1991 K. von Werder and M. Schulz: Prevention
and Therapy of Osteoporosis (in German).
Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany.
1992 R. Braun and M. Schulz: Guidance on
Patient Counselling in Case of Self-Medication (in German).
Govi Publishing Co., Eschborn, Germany.
1994 R. Braun and M. Schulz: Self-Treatment:
Counselling at the Pharmacy (in German).
Govi Publishing Co., Eschborn, Germany; 1st – 9th Supplement, 1996 – 2010.
1999 S. Mangiapane, M. Schulz and F.
Verheyen: Handbooks Pharmaceutical Care
(Eds.: Schaefer, M. and M. Schulz), Volume 2: Asthma (in German).
Govi Publishing Co., Eschborn, Germany. 4th edition 2005.
2000 M. Schaefer and M. Schulz: Handbooks
Pharmaceutical Care
(Eds.: Schaefer, M. and M. Schulz), Volume 1: Principles (in German).
Govi Publishing Co., Eschborn, Germany.
2003 H. Derendorf, M. Schulz and R. Wemhöner: Applied Pharmacology, 7th edition (in German).
Deutscher Apotheker Verlag, Stuttgart, Germany.
2004 C. Eckert-Lill, S. Schmitz, and M.
Schulz (eds.): Family Pharmacy (in German).
Govi Publishing Co., Eschborn, Germany.
TEACHING EXPERIENCE
Freie Universität Berlin, Institute of Pharmacy, Adjunct Professor (2015 – present)
WS 2015/16 – present 1 SH Pharmacoepidemiology and Pharmaco-Economics (lecture)
Goethe-University Frankfurt, School of Pharmacy, Adjunct Professor (2005 – present)
SS 2005 – WS 2016/17 1 SH
Pharmacotherapeutics (lecture): Respiratory System: Asthma &
COPD,
Cardiovascular System: Heart Failure & Hypertension
Pharmaceutical Care/Medicines Management (seminar): Basic Principles, Scientific Evaluation, Asthma
SS 2004 4 hrs. Pharmaceutical care: Depression (seminar)
WS 2004/05 4 hrs. Emergency contraception ("Morning After Pill")
SS 2005 4 hrs. Pharmaceutical care of cancer patients
WS 2005/06 4 hrs. Pharmaceutical care of HIV/AIDS patients
WS 2006/07 4 hrs. Histamine H1 receptor antagonists as hypnotics
SS 2007 4 hrs. Histamine H2 receptor antagonists
WS 2007/08 4 hrs. Obesity: Definition, classification, epidemiology, measurement, risk factors
SS 2008 4 hrs. Pharmaceutical care of patients with atopic dermatitis
WS 2008/09 4 hrs. Diseases of the respiratory tract: Pharmaceutical care
SS 2009 4 hrs. Headaches: Counseling in the pharmacy
SS 2010 4 hrs. Self-medication/OTC-Use: Analgesics and antipyretics
WS 2010/11 4 hrs. Demographic Change: Pharmaco-cconomic challenges
Goethe-University Frankfurt, School of Pharmacy, Invited Lecturer (2001 – 2005)
WS 2001/02 – 1 SH Principles of Evidence-based medicine, Pharmacoepidemiology,
SS 2004 Pharmaco-Economics, and Pharmaceutical Care (lecture)
WS 2004/05 4 hrs. Scientific evaluation of Pharmaceutical Care I and II (seminar)
University Hamburg, School of Medicine
WS 1986/87 1 hr. Colloquium Forensic Medicine (for students of law)
SS 1987 1 hr. Topics:
WS 1987/88 1 hr. Toxicology I: Exhibits, Accident - Suicide - Homicide, Assessment/Expert opinion
SS 1988 1 hr. Toxicology II: Analytics, Illegal drugs, Medicines, Pesticides
WS 1987/88 4 hrs. Course, Basic and Systematic Pharmacology and Toxicology (for medical students)
SS 1988 4 hrs. Course, Basic and Systematic Pharmacology and Toxicology (for medical students)
SS 1988 1 hr. Basic Toxicology (for food chemistry students)
University Marburg, School of Pharmacy
SS 1992 2 hrs. Seminar medicinal products: Analgesics
SS 1994 2 hrs. Seminar: Pharmaceutical care
WS 1995/96 2 hrs. Seminar medicinal products: Sedatives and hypnotics
WS 1999/00 2 hrs. Seminar medicinal products: Pharmaceutical care in Germany
WS 2000/01 2 hrs. Seminar medicinal products: Drug information
WS 2001/02 2 hrs. Seminar medicinal products: Drug information
University Saarbruecken, School of Pharmacy
SS 1999
2
hrs. Asthma: Diagnosis, therapy and problem-solving by pharmaceutical care (lecture)
Humboldt-University Berlin (Consumer Health Care Master Program)
SS 2001
4
hrs. Patient counseling in OTC-medicines (lecture)
Mandatory Pharmacy Intern Education (§ 4 (4) pharmacist licensing regulation)
March 1990, Univ. Frankfurt: Patient counseling (1) drug side/adverse effects
March 1991, Univ. Frankfurt: Patient counseling (2) drug/drug-interactions
Patient counseling (3) side-effects in pregnancy and pediatrics
September 1992 – August 1994 Intoxications and antidotes
Univ. Marburg and Univ. Frankfurt
Schools of Nursing
1983/84
Pharmacology/ Johanniter Hospital Geesthacht and
Pharmacotherapy Hospital Reinbek
St. Adolf-Stift
1986/87; 1987/88
Pharmacology/ University-Hospital Eppendorf, Hamburg
Pharmacotherapy
1986/87
Pharmacology/ University-Hospital Eppendorf, Hamburg,
Pharmacotherapy Intensive Care and
Anesthesiology
PhD STUDENTS
- Miriam Ude, Goethe-University Frankfurt, Department of Pharmacology/Clinical Pharmacy, Germany 2011: Evaluation der Adhärenz, Compliance und Persistenz bei Patienten unter antihypertensiver Therapie [Evaluation of medication adherence, compliance, and persistence with antihypertensives].
- Lea Botermann, Freie Universität Berlin, Department of Clinical Pharmacy, Germany 2016: Der Medikationsplan zur Verbesserung der Arzneimitteltherapiesicherheit in Deutschland: Analyse des Status quo und Evaluation der Verständlichkeit bei Patienten mit Polymedikation [Medication plan to improve medication safety in Germany: Analysis of status quo and evaluation of the comprehensibility by patients with polypharmacy].
EXTERNAL PhD/MSc/Dipl.-Pharm. EXAMINATIONS
- Alison Roberts, PhD – University of Sydney, Department of Pharmacy Practice, Australia 2006: Practice change in community pharmacy: The implementation of cognitive services.
- Alexandros Liakos, Dipl.-Pharm./MSc – University of Bonn, Department of Clinical Pharmacy, Germany 2008: Drug-related problems in diabetic patients.
- Teresa Margarida Mealha Salgado, PhD – University of Lisbon, Faculty of Pharmacy, Department of Social Pharmacy, Portugal 2013: The role of pharmacists on outpatients undergoing hemodialysis.
- Gudrun Vogel, PhD – University of Bonn, Department of Clinical Pharmacy, Germany 2013: Management von Arzneimittelinteraktionen in der öffentlichen Apotheke [Management of drug/drug-interactions in community pharmacy practice].
- Eimear Bridget O’Dwyer, MSc –Trinity College Dublin, School of Pharmacy, Department of Pharmacy Practice, Ireland 2014: An evaluation of a medicines information service for palliative care.
- Katrin Krueger, Dipl.-Pharm./MSc – University Halle-Wittenberg, Institute of Pharmacy, Germany 2017: Methoden zur Analyse von Sekundärdaten zur Bestimmung der Medikamenten-Adhärenz bei chronischer Herzinsuffizienz – eine systematische Übersicht [Analyzing medication adherence in patients with chronic heart failure – a systematic review].
- Danny Brell, PhD – University Witten/Herdecke, Department of Medicine, Germany 2018: Erprobung eines Medikationsplanes in der Praxis hinsichtlich Akzeptanz und Praktikabilität – Modellregion Erfurt [Testing the feasibility of a medication plan in daily practice – model region Erfurt].
- Paul Steinborn, DDS – Charité – Universitätsmedizin Berlin, Institute of Physiology, Germany, 2019: Analyse der schmerztherapeutischen Entlassungsmedikation an der Charité – Universitätsmedizin Berlin [Analysis of the analgesic discharge medication at Charité – Universitätsmedizin Berlin].
-
Sandra Prescher, Dr. rer. medic. – Charité – Universitätsmedizin Berlin, Center for Cardiovascular Telemedicine, Department of Cardiology and Angiology,
Germany, 2020: Adhärenz zur telemedizinischen Mitbetreuung von Patienten mit chronischer Herzinsuffizienz
– eine retrospektive Analyse der randomisierten, kontrollierten Studien TIM-HF und TIM-HF2 [Adherence to telemonitoring by patients with chronic heart failure – a retrospective analysis of TIM-HF
and TIM-HF2].
- Alaa Fakher, MSc Pharm. Sciences – Freie Universität Berlin/Charité – Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapy, Germany 2020: Impact of S100A8/A9 inhibitor paquinimod on S100A8/A9-induced cardiac inflammation and fibrosis: an in vitro evaluation.
REQUESTED ACADEMIC
REFERENCES
- School of Pharmacy, University of Manchester, UK 2010: Promotion to Chair (Full Professor).
- Institute of Pharmacy,
Leopold-Franzens-University Innsbruck, A 2020: Full Professor Clinical Pharmacy.
- Faculty of Pharmacy, University of Kuwait, 2020: Promotion to Associate
Professor.
REQUESTED SCIENTIFIC EVALUATIONS
- Netherlands Institute for Health Services Research (NIVEL). Utrecht, the Netherlands.
- Swiss National Science Foundation. Bern, Switzerland.
LINKS